Clinical Trial Update: Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erythropoietin for protection against necrotizing enterocolitis in very preterm infants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Necrotizing Enterocolitis
• Premature Infant

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Zhengzhou University | Conditions: Premature Infant | Phase 2 | Status: COMPLETED